Hyperhidrosis: primary focal vs secondary — the AU general practice approach

Hyperhidrosis is sweating in excess of the body’s physiological need for thermoregulation. Eccrine sweat glands across the body surface are innervated by cholinergic sympathetic fibres, and in primary focal hyperhidrosis those fibres fire in excess without structural cause. The result is embarrassing, disabling, and — because the condition is rarely discussed — remarkably underdiagnosed in Australian general practice.

Around 3% of Australians are estimated to have primary focal hyperhidrosis, yet the average time from symptom onset to first medical consultation is nine years, and approximately half of affected people have never raised the problem with a clinician (Australasian College of Dermatologists). Quality-of-life scores in this group match severe psoriasis. Treatments exist at every point on the spectrum from inexpensive over-the-counter options to Medicare-supported procedures.

A. Core clinical — the AU general-practice framework

History

The RACGP and Australasian College of Dermatologists both recommend a structured assessment to separate primary focal from secondary hyperhidrosis.

Diagnostic criteria for primary focal hyperhidrosis (Hornberger 2004): focal, visible, excessive sweating ≥6 months without apparent cause, plus at least two of: bilateral and symmetric distribution; impairs daily activities; at least one episode per week; age at onset under 25; positive family history; cessation during sleep. The cessation during sleep criterion is the single most clinically useful discriminator — primary focal hyperhidrosis switches off when the cortical drive to the sympathetic chain is silenced at night.

Key history points:

• Onset age and speed — gradual since childhood or adolescence suggests primary; abrupt adult onset suggests secondary
• Distribution — bilateral symmetric focal sites (axillae most common, then palms, soles, and face) versus generalised or asymmetric
• Nocturnal pattern — primary focal hyperhidrosis does not produce night sweats; nocturnal drenching mandates secondary workup
• Triggers — heat, emotion, caffeine, spicy food, alcohol in primary; paroxysmal episodes in phaeochromocytoma; flushing with diarrhoea and wheeze in carcinoid
• Drug history — SSRIs, SNRIs, opioids, lithium, sulfonylureas, anticholinesterase inhibitors, withdrawal states
• Psychosocial impact — school, work, relationships, clothing, anxiety, depression

Severity grading: The Hyperhidrosis Disease Severity Scale (HDSS) is a single validated four-point question: 1 = never noticeable; 2 = tolerable but sometimes interferes; 3 = barely tolerable and frequently interferes; 4 = intolerable and always interferes. HDSS ≥ 2 warrants treatment escalation. An HDSS ≥ 3 with documented quality-of-life impairment meets the PBS threshold for botulinum toxin.

Examination

Most primary focal hyperhidrosis presentations need no investigation — the diagnosis is clinical. Examine for:

• General: weight, blood pressure and pulse (tachycardia and hypertension suggest thyroid or phaeochromocytoma), tremor
• Lymph nodes: cervical, axillary, supraclavicular, inguinal (lymphoma)
• Skin distribution: symmetric bilateral focal (primary) versus generalised or asymmetric
• Thyroid on palpation if history suggests; goitre

Investigations

Only order investigations when a secondary cause is clinically plausible. Targeted workup includes:

• TSH — hyperthyroidism
• Fasting glucose and HbA1c — diabetic autonomic neuropathy or hypoglycaemia
• Full blood count, LDH, ESR/CRP — lymphoma workup
• Plasma free metanephrines — paroxysmal pattern with headache, hypertension, and palpitations
• 24-hour urinary 5-HIAA — suspected carcinoid (sweating plus flushing, diarrhoea, wheeze)
• HIV and tuberculosis IGRA if B-symptoms or risk factors

B. Evidence base — treatment ladder from topical to surgical

Therapeutic Guidelines (eTG) and the International Hyperhidrosis Society align on a stepwise approach.

Step 1 — Aluminium chloride hexahydrate 20% (Drysol)

First-line across all sites. Applied to dry skin at night — the dry-skin requirement is critical because moisture causes an irritant reaction that leads patients to abandon treatment. Apply nightly for one to two weeks during induction, then reduce to once or twice weekly maintenance. Mild hydrocortisone 1% manages irritation. Available over the counter for approximately $25 per 35 mL bottle; no prescription required.

Step 2 — Iontophoresis (palms and soles)

Tap water iontophoresis uses low-voltage direct current (15–20 mA for 20–30 minutes) to suppress eccrine gland output. Induction requires three to four sessions per week for four to six weeks, then one to two per week maintenance. Effective in approximately 80% of palmar and plantar disease. Home devices cost $500–$1,200. Contraindicated in pregnancy and in patients with pacemakers or metal implants in the current path.

Step 3 — Intradermal botulinum toxin A (axillary disease)

Heckmann et al (NEJM 2001) demonstrated 82% reduction in axillary sweat production at four weeks with botulinum toxin A, durable to seven months, in an RCT. Effect typically lasts three to nine months per treatment. PBS Authority Required for severe axillary disease meeting HDSS ≥ 3 plus DLQI thresholds, prescribed or initiated by a dermatologist or neurologist. Off-label palmar, plantar, and craniofacial applications are privately funded.

Step 4 — Oral oxybutynin (multifocal or craniofacial disease)

Wolosker et al (Clin Auton Res 2014) showed improvement across multifocal disease with oxybutynin 2.5 mg at night titrated to 5 mg twice daily. The anticholinergic side-effect profile — dry mouth in approximately 70%, constipation, urinary retention, blurred vision — limits use, particularly in older patients. Per AMH, use lowest effective dose and monitor for cognitive effects in those over 65.

Step 5 — Microwave thermolysis (miraDry) and endoscopic thoracic sympathectomy (ETS)

MiraDry targets axillary eccrine glands non-invasively and achieves approximately 70% durable reduction in one to two sessions; privately funded at $2,500–$4,000 per session. ETS surgically disrupts the thoracic sympathetic chain and is highly effective for palmar and craniofacial disease, but compensatory sweating develops in 30–90% of patients — sometimes worse than the original — making it a last resort (Cerfolio Ann Thorac Surg 2011). Explicit compensatory-sweating counselling before consent is mandatory.

C. Distinguishing primary from secondary hyperhidrosis

The nocturnal pattern is the most important discriminator in general practice. Primary focal hyperhidrosis does not produce night sweats — the cortical drive to the sympathetic chain is silenced during sleep. Any patient reporting nocturnal drenching needs secondary workup regardless of the focal distribution of their daytime sweating.

Red flags requiring secondary workup:

• Night sweats — lymphoma, tuberculosis, HIV, endocarditis, phaeochromocytoma, menopause
• Asymmetric or unilateral distribution — neurological cause (Horner syndrome, Harlequin syndrome, Frey syndrome, post-stroke, Pancoast tumour)
• New-onset after age 25 without childhood history — secondary cause likely
• Paroxysmal sweating with headache, palpitations, hypertension — phaeochromocytoma until proven otherwise
• Sweating plus flushing, diarrhoea, wheeze — carcinoid syndrome
• B-symptoms (weight loss, fever, lymphadenopathy) — lymphoma or tuberculosis

Drug-induced sweating is a frequently missed secondary cause. SSRIs and SNRIs — particularly venlafaxine and paroxetine — cause clinically significant sweating in 14–22% of users. Reviewing the medication list before escalating treatment for presumed primary hyperhidrosis is important clinical practice per NPS MedicineWise.

D. Australian operations

PBS-listed treatments:

• Aluminium chloride hexahydrate 20% — over-the-counter, not PBS-listed; approximately $25 per bottle
• Oxybutynin — PBS general schedule (listed for overactive bladder; off-label for hyperhidrosis is accepted in practice)
• Botulinum toxin type A — PBS Authority Required for severe primary axillary hyperhidrosis meeting HDSS and quality-of-life thresholds; specialist-initiated; verify current PBS item and quantity limits at www.pbs.gov.au
• Glycopyrrolate — not currently PBS-listed in Australia; available via compounding pharmacy private prescription

MBS items relevant to general practice:

• Standard GP consultation items 23, 36, 44 for assessment and follow-up
• Telehealth items for review of stable primary focal hyperhidrosis on established topical treatment
• Mental Health Care Plan item 2715 for social anxiety, depression, or avoidance behaviour

Mental health burden: Social anxiety and avoidance are near-universal consequences of untreated hyperhidrosis. A Mental Health Care Plan (item 2715) with referral to a psychologist trained in cognitive behavioural therapy for social anxiety is appropriate when psychosocial impact is significant. Screen specifically for depression and suicidality in adolescents.

GP Chronic Care Management Plan (GPCCMP): Applicable when primary focal hyperhidrosis overlaps with a qualifying chronic condition — anxiety disorder, obesity, menopause, type 2 diabetes — enabling allied health sessions (psychologist, exercise physiologist, dietitian).

Follow-up cadence: Review at two weeks after starting aluminium chloride to check technique and irritation; at six weeks to assess response and consider escalation (HDSS repeat); three-monthly for botulinum toxin patients; annually for those stable on topical or iontophoresis.

E. Special populations

Adolescents. Primary focal hyperhidrosis often begins in childhood and peaks around puberty. Palmar and plantar involvement is common. Bullying, school avoidance, and social phobia are significant risks. Mental health screening including explicit suicidality assessment is mandatory at every visit. Informed consent for off-label treatments must be obtained from parents and the young person jointly.

Older adults. Oxybutynin carries cumulative anticholinergic burden (Beers criteria) and increases dementia and delirium risk in those over 65. Prefer topical aluminium chloride, iontophoresis, or botulinum toxin over systemic anticholinergics. Check for polypharmacy — anticholinesterase inhibitors (donepezil) used for cognitive decline can themselves cause sweating.

Pregnancy. Aluminium chloride is considered safe. Iontophoresis is contraindicated. Botulinum toxin — avoid due to insufficient human safety data. Oxybutynin — not recommended in pregnancy. Refer to HealthDirect for consumer guidance.

Patients with comorbid menopause. Vasomotor sweating of menopause and primary focal hyperhidrosis can coexist. Menopausal hormone therapy addresses the vasomotor component but does not reduce the focal autonomic overactivity of primary focal hyperhidrosis; both may need separate management streams. Venlafaxine and paroxetine — sometimes used for menopausal symptoms — can themselves worsen sweating.

Aboriginal and Torres Strait Islander patients. Screen for secondary causes in keeping with higher baseline cardiovascular and metabolic risk. Apply culturally safe communication about body concerns; the Better Health Channel has consumer-facing resources in plain language.

When to escalate

Refer or escalate when:

• Diagnosis is uncertain after clinical assessment — dermatology for diagnostic clarification
• Primary focal hyperhidrosis refractory to eight to twelve weeks of aluminium chloride plus adequate iontophoresis trial — routine dermatology referral for botulinum toxin candidacy or miraDry discussion
• Severe HDSS 4 with major psychosocial impact, especially in adolescents — semi-urgent dermatology
• Secondary endocrine cause confirmed — endocrinology
• Suspected lymphoma or malignancy — semi-urgent haematology or oncology
• Significant comorbid depression, social phobia, or suicidality — specialist mental health; use Mental Health Care Plan
• Consideration of endoscopic thoracic sympathectomy — refer to thoracic surgery only after exhausting all other options and only with explicit compensatory-sweating counselling documented

What this article is and is not

This is general health information compiled from current Australian general practice and dermatology guidelines — Therapeutic Guidelines, Australasian College of Dermatologists, International Hyperhidrosis Society, NPS MedicineWise, Australian Medicines Handbook, and peer-reviewed trial evidence. It is not personal medical advice and does not create a doctor–patient relationship. Decisions about specific treatments, including botulinum toxin and surgery, are made with your own GP and treating specialists.

For Australian consumer resources: HealthDirect — Hyperhidrosis, Australasian College of Dermatologists patient leaflet, Better Health Channel, International Hyperhidrosis Society patient resources.

---

Sources cited

1. RACGP — Hyperhidrosis (Australian Family Physician 2013)
2. Therapeutic Guidelines (eTG) — Dermatology: Hyperhidrosis
3. Australasian College of Dermatologists — A–Z of Skin: Hyperhidrosis
4. International Hyperhidrosis Society — clinical resources
5. Australian Medicines Handbook
6. NPS MedicineWise
7. TGA — botulinum toxin product information
8. HealthDirect — Excessive sweating (hyperhidrosis)
9. Better Health Channel — Sweating and hyperhidrosis
10. Hornberger et al — Diagnostic criteria for primary focal hyperhidrosis (J Am Acad Dermatol 2004)
11. Heckmann et al — Botulinum toxin A for axillary hyperhidrosis (NEJM 2001)
12. Wolosker et al — Oxybutynin for hyperhidrosis (Clin Auton Res 2014)
13. Cerfolio et al — ETS and compensatory sweating (Ann Thorac Surg 2011)